Search clinical trials for: The Box 2.0

Total 17211 results

University Hospital, Geneva

Unknown

Drug Metabolism and Antidepressant (METADEP)

Depression

Switzerland
Fred Hutchinson Cancer Center
PromiCell Therapeutics, Inc.

Not yet recruiting

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Metastatic NUT Carcinoma | Unresectable NUT Carcinoma | Advanced NUT Carcinoma

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI); AbbVie

Withdrawn

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Richter Syndrome | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
Affini-T Therapeutics, Inc.

Recruiting

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Metastatic Colorectal Adenocarcinoma | Stage IV Lung Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8

United States
Yazeed Sawalha

Recruiting

Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

PRETEXT I Hepatoblastoma | PRETEXT II Hepatoblastoma | PRETEXT III Hepatoblastoma | PRETEXT IV Hepatoblastoma

United States, Canada, Puerto Rico, Australia, Japan, Brazil
National Cancer Institute (NCI)

Suspended

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic Osteosarcoma | Localized Osteosarcoma | High Grade Osteosarcoma | Secondary Osteosarcoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Ann Arbor Stage III Non-Hodgkin Lymphoma | Ann Arbor Stage IV Non-Hodgkin Lymphoma | Ann Arbor Stage II Non-Hodgkin Lymphoma

United States
University of Arkansas
Amgen

Terminated

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Stage I Adrenal Cortical Carcinoma AJCC v7 | Stage II Adrenal Cortical Carcinoma AJCC v7 | Stage III Adrenal Cortical Carcinoma AJCC v7 | Stage IV Adrenal Cortical Carcinoma AJCC v7

United States, Canada, Australia, Brazil
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Metastatic Malignant Neoplasm in the Bone | Peripheral Primitive Neuroectodermal Tumor of Soft Tissues | Metastatic Malignant Neoplasm in the Lung | Metastatic Ewing Sarcoma | Metastatic Malignant Neoplasm in the Bone Marrow | Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone

United States, Canada, Puerto Rico
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic Lymphoma | B Lymphoblastic Lymphoma | Recurrent T Lymphoblastic Leukemia/Lymphoma | Refractory T Lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia | T...

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Richter Syndrome | Refractory Transformed Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Sarcoma | Rhabdomyosarcoma | Adult Rhabdomyosarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Embryonal Rhabdomyosarcoma | Childhood Botryoid-Type Embryonal Rhabdomyosarcoma | Localized Childhood Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma AJCC v7 | Stage II Adult Soft Tissue Sarcoma... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
National Cancer Institute (NCI)

Suspended

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Locally Advanced Uterine Corpus Leiomyosarcoma | Metastatic Uterine Corpus Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Uterine Corpus Leiomyosarcoma

United States, Puerto Rico
St. Jude Children's Research Hospital
Cookies for Kids' Cancer; CURE Childhood Cancer, Inc.

Active, not recruiting

Therapy for Children With Advanced Stage Neuroblastoma

Neuroblastoma

United States
M.D. Anderson Cancer Center

Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Diffuse Large B-Cell Lymphoma Unclassifiable

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

HIV Infection | Recurrent Grade 3 Follicular Lymphoma | Plasmablastic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Primary Effusion Lymphoma | AIDS-Related Primary Effusion Lymphoma | Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Acute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Burkitt Lymphoma | AIDS-Related Burkitt Lymphoma | Atypical Burkitt/Burkitt-Like Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; North Central...

Active, not recruiting

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Breast Adenocarcinoma

United States, Peru, South Africa
Children's Oncology Group
National Cancer Institute (NCI); University College, London; Medical Research...

Completed

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (EURAMOS-1)

Metastatic Osteosarcoma | Localized Osteosarcoma

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Recurrent T-Cell... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Suspended

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Basaloid Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Papillary Squamous Cell Carcinoma | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditions

United States, Canada
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy; California Institute for Regenerative... and other collaborators

Recruiting

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast Cancer | Neuroendocrine Tumors | Lung Adenocarcinoma | Metastatic Melanoma | Head and Neck Squamous Cell Carcinoma | Refractory Malignant Solid Neoplasm | Thyroid Cancer | Pheochromocytoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Malignant Germ Cell Tumor | Germ Cell Tumor | Childhood Extracranial Germ Cell Tumor | Extragonadal Embryonal Carcinoma | Malignant Ovarian Teratoma | Stage I Ovarian Choriocarcinoma | Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 | Stage I Ovarian Teratoma AJCC v6 and v7 | Stage I Ovarian Yolk... and other conditions

United States, Canada, Australia, Puerto Rico, New Zealand, Saudi Arabia, United Kingdom, India, Japan
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
GOG Foundation
National Cancer Institute (NCI)

Completed

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

Hydatidiform Mole | Choriocarcinoma | FIGO Stage I Gestational Trophoblastic Tumor | FIGO Stage II Gestational Trophoblastic Tumor | FIGO Stage III Gestational Trophoblastic Tumor

United States, Korea, Republic of, Canada, Japan, United Kingdom
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
Mayo Clinic

Recruiting

Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Rhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma

United States, Canada, Puerto Rico, Australia, New Zealand
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD)

Cardiovascular Diseases | Coronary Disease | Hypertension | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Atherosclerosis | Hypercholesterolemia

United States, Canada

Search clinical trials for: The Box 2.0

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations